New advances in synthetic methodologies that allow rapid access to a wide variety of
functionalized heterocyclic compounds are of critical importance to the medicinal chemist as …

Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common
type of dementia in the elderly. The clinical symptoms of AD include a progressive loss of …

Fluorinated organic molecules are increasingly being prepared for a variety of applications,
including pharmaceutical products. However, the supply chain to access the necessary raw …

Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1, 2, 4-thiadiazinane 1, 1-
dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 …

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that effects 50 million
people worldwide. In this review, AD pathology and the development of novel therapeutic …

A growing body of pathological, biomarker, genetic, and mechanistic data suggests that
amyloid accumulation, as a result of changes in production, processing, and/or clearance of …

The amyloid hypothesis has long been the central dogma in drug discovery for Alzheimer's
disease (AD), leading to many small-molecule and biological drug candidates. One major …

Alzheimer's disease (AD) is an irreversible, progressive neurological disorder characterized
by amyloid plaques, hyperphosphorylated tau protein (hyper p-tau), neuronal damage …

There are many biologically active organic molecules that contain one or more nitrogen-
containing moieties, and broadly applicable and efficient catalytic transformations that …

Abstract β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the
potential of disease-modifying treatment for Alzheimer's disease (AD). Since 2014, major …